CRBU vs UNH

Caribou Biosciences (CRBU) presents a high-risk, high-reward profile driven by its innovative CRISPR 'off-the-shelf' CAR-T platform. The significant boost to its score reflects the recent FDA RMAT designation for CB-011, based on compelling Phase 1 data (92% ORR). This materially de-risks a key asset and accelerates its path to market leadership in a vast oncology segment. Strong Q4 2025 earnings ...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...